 Connection
Thomas Bak to Immunosuppressive Agents
This is a "connection" page, showing publications Thomas Bak has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.222 |
|
|
|
-
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother. 2007 Jun; 8(9):1275-82.
Score: 0.053
-
Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2003 Jul; 9(7):727-32.
Score: 0.040
-
Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003 May; 9(5):463-8.
Score: 0.040
-
Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transpl. 2002 Mar; 8(3):212-8.
Score: 0.037
-
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008 Sep; 14(9):1281-6.
Score: 0.014
-
Florman S, Alloway R, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27; 83(12):1639-42.
Score: 0.013
-
Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int. 2007 Sep; 20(9):747-53.
Score: 0.013
-
Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003 Nov; 9(11):1159-65.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|